Hans Moebius
Technik-/Wissenschafts-/F&E-Leiter bei Exciva GmbH
Vermögen: 175 645 $ am 30.04.2024
Aktive Positionen von Hans Moebius
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Exciva GmbH
Exciva GmbH Miscellaneous Commercial ServicesCommercial Services Exciva GmbH is a clinical stage biopharmaceutical company located in Heidelberg, Germany. Exciva is focused on delivering an innovative treatment to address symptoms of Alzheimer's patients. The German company's main product, Deraphan©, is a combination of two clinically validated products that act on well-documented pharmacological pathways in the field of neuropsychiatry. The symptoms that Exciva aims to address are the Behavioral and Psychological Symptoms in Demented patients (BPSD), which appear in clusters with aging and are particularly prevalent in Alzheimer's disease. The company was founded by Hans Moebius and the CEOs are Bespalov Anton and François Conquet. | Technik-/Wissenschafts-/F&E-Leiter | 01.04.2020 | - |
Karriereverlauf von Hans Moebius
Ehemalige bekannte Positionen von Hans Moebius
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
ATHIRA PHARMA, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.04.2019 | 05.01.2024 |
Exciva GmbH
Exciva GmbH Miscellaneous Commercial ServicesCommercial Services Exciva GmbH is a clinical stage biopharmaceutical company located in Heidelberg, Germany. Exciva is focused on delivering an innovative treatment to address symptoms of Alzheimer's patients. The German company's main product, Deraphan©, is a combination of two clinically validated products that act on well-documented pharmacological pathways in the field of neuropsychiatry. The symptoms that Exciva aims to address are the Behavioral and Psychological Symptoms in Demented patients (BPSD), which appear in clusters with aging and are particularly prevalent in Alzheimer's disease. The company was founded by Hans Moebius and the CEOs are Bespalov Anton and François Conquet. | Vorstandsvorsitzender | 01.01.2016 | 01.01.2019 |
Technik-/Wissenschafts-/F&E-Leiter | 01.01.2016 | 01.01.2019 | |
Gründer | 01.01.2016 | 01.01.2019 | |
Rodin Therapeutics, Inc.
Rodin Therapeutics, Inc. BiotechnologyHealth Technology Rodin Therapeutics, Inc. develops first in class therapeutics for cognitive disorders. The company was founded by Bruce Booth in 2013 and is headquartered in Cambridge, MA. | Technik-/Wissenschafts-/F&E-Leiter | 01.12.2016 | 01.04.2018 |
Chase Pharmaceuticals Corp.
Chase Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Chase Pharmaceuticals Corp. develops novel medications for the treatment of Alzheimer’s disease. It focuses on pharmaceuticals for Alzheimer type dementia, which include oral medications such as its lead product, CPC-201, as well as CPC 252 for transdermal administration. The company was founded by Thomas N. Chase and Kathleen Clarence-Smith in 2007 and is headquartered in Washington, DC. | Technik-/Wissenschafts-/F&E-Leiter | - | 01.01.2016 |
Ausbildung von Hans Moebius
Ruprecht-Karls-Universität Heidelberg | Doctorate Degree |
Technische Universität Kaiserslautern | Undergraduate Degree |
Statistik
International
Vereinigte Staaten | 4 |
Deutschland | 4 |
Operativ
Chief Tech/Sci/R&D Officer | 5 |
Chief Executive Officer | 1 |
Founder | 1 |
Sektoral
Health Technology | 4 |
Consumer Services | 3 |
Commercial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
ATHIRA PHARMA, INC. | Health Technology |
Private Unternehmen | 3 |
---|---|
Chase Pharmaceuticals Corp.
Chase Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Chase Pharmaceuticals Corp. develops novel medications for the treatment of Alzheimer’s disease. It focuses on pharmaceuticals for Alzheimer type dementia, which include oral medications such as its lead product, CPC-201, as well as CPC 252 for transdermal administration. The company was founded by Thomas N. Chase and Kathleen Clarence-Smith in 2007 and is headquartered in Washington, DC. | Health Technology |
Rodin Therapeutics, Inc.
Rodin Therapeutics, Inc. BiotechnologyHealth Technology Rodin Therapeutics, Inc. develops first in class therapeutics for cognitive disorders. The company was founded by Bruce Booth in 2013 and is headquartered in Cambridge, MA. | Health Technology |
Exciva GmbH
Exciva GmbH Miscellaneous Commercial ServicesCommercial Services Exciva GmbH is a clinical stage biopharmaceutical company located in Heidelberg, Germany. Exciva is focused on delivering an innovative treatment to address symptoms of Alzheimer's patients. The German company's main product, Deraphan©, is a combination of two clinically validated products that act on well-documented pharmacological pathways in the field of neuropsychiatry. The symptoms that Exciva aims to address are the Behavioral and Psychological Symptoms in Demented patients (BPSD), which appear in clusters with aging and are particularly prevalent in Alzheimer's disease. The company was founded by Hans Moebius and the CEOs are Bespalov Anton and François Conquet. | Commercial Services |
- Börse
- Insiders
- Hans Moebius
- Erfahrung